Abstract 5553
Background
High inflammatory cytokine levels can lead to severe fatigue and alter the quality of life (QoL) of family caregivers (FCGs) of patients with head and neck cancer in palliative care (HNCPC). In addition, single nucleotide variants (SNVs) in cytokine genes, such as IL1B c-598T>C (rs16944), IL1R2 c.-2009G>A (rs4141134), IL6 c.-237G>C (rs1800795), and TREML2 c.430A>G (rs3747742), can influence individual differences in cytokine production. However, the roles of the referred SNVs on the QoL of FCGs are unknown. Thus, the aim of our study was to evaluate the influence of the referred SNVs in the QoL of FCGs of patients with HNCPC.
Methods
Genomic DNA of 100 FCGs of patients with HNCPC was analyzed by real-time PCR to identify the genotypes. QoL was measured with the abbreviated World Health Organization QoL questionnaire (WHOQOL-bref). The cut-off of the score was lower than 60 for worse QoL. Differences between groups were assessed by Fisher’s exact test, chi-square (bivariate analysis), and multiple linear regression.
Results
FCGs who carried IL6 GG (62.8% vs. 49.2%, odds ratio [OR]: 2.78, 95% confidence interval [CI]: 1.03-7.44, p = 0.04) and TREML2 AA (60.0% vs. 44.6%, OR: 2.68, 95% CI: 1.03-7.01, p = 0.04) had worse QoL for the overall QoL domain than non-carriers. The frequency of the genotype TREML2 AA was higher in FCGs with lower score for physical domain (61.0% vs. 42.4%, OR: 2.69, 95% CI: 1.05-6.87, p = 0.03). FCGs who carried IL1B TT genotype had worse QoL for the social domain than others (48.9% vs. 32.1%, OR: 3.49, 95% CI: 1.03-7.01, p = 0.01).
Conclusions
Genotypes of the IL1B, IL6, and TREML genes, associated with higher inflammatory levels, seem to influence the QoL of FCGs. We believe that our results can contribute to identify FCGs with worse QoL for physical, psychological, and social aspects and provide better and more specialized care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract